Page 1132 - Basic _ Clinical Pharmacology ( PDFDrive )

1118 SECTION X Special Topics

REFERENCES Kent AJ: Pharmacologic management of diarrhea. Gastroenterol Clin N Am 2010;
39:496.
Acid-Peptic Diseases Li Z et al: Treatment of chronic diarrhea. Best Pract Clin Gastroenterol 2012;
Alshamsi F et al: Efficacy and safety of proton pump inhibitors for stress ulcer 26:677.
prophylaxis in critically ill patients: A systematic review and meta-analysis of
randomized trials. Crit Care 2016;20:120. Drugs Used for Irritable Bowel Syndrome
Barletta JF et al: Stress ulcer prophylaxis. Crit Care Med 2016;44:1395.
Bredenoord AJ et al: Gastro-oesophageal reflux disease. Lancet 2013; Chang L et al: 2015 James W. Freston Topic Conference: A renaissance in
the understanding and management of irritable bowel syndrome. Clin
381(9881):1933. Gastroenterol Hepatol 2016;14:e77.
Fallone CA et al: The Toronto Consensus for the treatment of Helicobacter pylori Chey WD et al: Linaclotide for irritable bowel syndrome with constipation: A
infection in adults. Gastroenterology 2016;151:51. 26-week randomized, double-blind, placebo-controlled trial to evaluate
Ford AC et al: Eradication therapy for peptic ulcer disease in Helicobacter pylori- efficacy and safety. Am J Gastroenterol 2012;107:1702.
positive people. Cochrane Database Syst Rev 2016;4:CD003840. Ford AC et al: American College of Gastroenterology monograph on the manage-
Gerson L: Proton pump inhibitors and potential interactions with clopidogrel: An ment of irritable bowel syndrome and chronic idiopathic constipation. Am J
update. Curr Gastroenterol Rep 2013;15:329. Gastroenterol 2014;109(Suppl 1):S2.
Gomm W et al: Association of proton pump inhibitors with risk of dementia. Lembo AJ et al: Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J
JAMA Neurol 2016;73:410. Med 2016;374(3):242.
Katz PO et al: Guidelines for the diagnosis and management of gastroesophageal Vazquez RM et al: Linaclotide, a synthetic guanylate cyclase C agonist, for the
reflux disease. Am J Gastroenterol 2013;108:308. treatment of functional gastrointestinal disorders associated with constipa-
Lazarus B et al: Proton pump inhibitor use and the risk of chronic kidney disease. tion. Exp Rev Gastroenterol Hepatol 2011;5:301.
JAMA Intern Med 2016;176:238.
Malfertheiner P et al: Management of Helicobacter pylori infection—the Maastricht Antiemetic Agents
IV/Florence Consensus report. Gut 2012;61:646.
Medlock S et al: Co-prescription of gastroprotective agents and their efficacy in Basch E et al: Antiemetics: American Society of Clinical Oncology Clinical
elderly patients taking nonsteroidal anti-inflammatory drugs: A systematic Practice Guideline update. J Clin Oncol 2011;29:4189.
review of observational studies. Clin Gastroenterol Hepatol 2013;11:1259. Ettinger DS et al: Antiemesis. J Natl Canc Comp Netw 2012;10:456.
Scheiman JM: The use of proton pump inhibitors in treating and preventing Jordan K et al: Recent developments in the prevention of chemotherapy-induced
NSAID-induced mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S5. nausea and vomiting (CINV): A comprehensive review. Ann Oncol 2015;
Schubert ML: Gastric secretion. Curr Opin Gastroenterol 2014;30:578. 26:1081.
Sigterman KE et al: Short-term treatment with proton pump inhibitors, Navarri R et al: Antiemetic prophylaxis for chemotherapy-induced nausea and
H2-receptor antagonists, and prokinetics for gastro-oesophageal reflux vomiting. N Engl J Med 2016;374:1356.
disease-like symptoms and endoscopy negative reflux disease. Cochrane Navarri R et al: Olanzapine for the prevention of chemotherapy-induced nausea
Database Syst Rev 2013;5:CD002095. and vomiting. N Engl J Med 2016;375:134.

Motility Disorders Drugs Used for Inflammatory Bowel Disease
Camilleri M et al: Clinical guideline: Management of gastroparesis. Am J Gastro- Bloomgren G et al: Risk of natalizumab-associated progressive multifocal leukoen-
enterol 2013;108:18. cephalopathy. N Engl J Med 2012;366:20.
Enweluzo C et al: Gastroparesis: A review of current and emerging treatment Bressler B et al: Clinical guidelines for the medical management of nonhospitalized
options. Clin Exp Gastroenterol 2013;6:161. ulcerative colitis: The Toronto consensus. Gastroenterology 2015;148:1035.
Farmer AD: Diabetic gastroparesis: Pathophysiology, evaluation and management. Casteelle N et al: Trough concentrations of infliximab guide dosing for patients
Br J Hosp Med 2012;73:451. with inflammatory bowel disease. Gastroenterology 2015;148:1320.
Cheifetz AS et al: Management of active Crohn disease. JAMA 2013;309:2150.
Laxatives Ford AC et al: Efficacy of biological therapies in inflammatory bowel disease: A
systematic review and meta-analysis. Am J Gastroenterol 2011;106:644.
Bharucha AE et al: American Gastroenterological Association Medical Position Ford A et al: Efficacy of oral vs. topical, or combined oral and topical
Statement on constipation. Gastroenterology 2013;144:211. 5-aminosalicylates in ulcerative colitis: A systematic review and meta-
Brenner DM et al: Chronic constipation. Gastroenterol Clin North Am analysis. Am J Gastroenterol 2012;107:167.
2016;45:205. Ford A et al: Ulcerative colitis. BMJ 2013;346:f432.
Brock C et al: Opioid-induced bowel dysfunction: Pathophysiology and manage- Kotlyar DS et al: Risk of lymphoma in patients with inflammatory bowel disease
ment. Drugs 2012;72:1847. treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin
Ford AC et al: Laxatives for chronic constipation in adults. BMJ 2012;345:e6168. Gastroenterol Hepatol 2015;13:847.
Johnson DA et al: Optimizing adequacy of bowel cleansing for colonoscopy: Mosli MH et al: Vedolizumab for induction and maintenance of remission in
Recommendations from the US Multisociety Task Force on Colorectal ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm
Cancer. Gastroenterology 2014;147:903. Bowel Dis 2015;21:1151.
Kilgore TW et al: Bowel preparation with split-dose polyethylene glycol before Ordas I: Ulcerative colitis. Lancet 2012;380:1606.
colonoscopy: A meta-analysis of randomized controlled trials. Gastrointest Pola S et al: Strategies for the care of adults hospitalized for active ulcerative colitis.
Endosc 2011;73:1240. Clin Gastroenterol Hepatol 2012;10:1315.
Linaclotide (Linzess) for constipation. Med Lett Drugs Ther 2012;54:91. Sandborn WJ et al: Adalimumab induces and maintains clinical remission in patients
Schey R et al: Lubiprostone for the treatment of adults with constipation and with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257.
irritable bowel syndrome. Dig Dis Sci 2011;56:1619. Sandborn WJ et al: Subcutaneous golimumab induces clinical response and remis-
Wald A: Constipation: Advances in diagnosis and treatment. JAMA 2016;315:185. sion in patients with moderate to severe ulcerative colitis. Gastroenterology
2014;146:85.
Antidiarrheal Agents Sandborn WJ et al: Subcutaneous golimumab maintains clinical response in patients
with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96.
Camilleri M: Bile acid diarrhea: Prevalence, pathogenesis, and therapy. Gut Liver Sandborn WJ et al: Vedolizumab as induction and maintenance therapy for
2015;9:332. Crohn’s disease. N Engl J Med 2013;369:711.